Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
$83.49
-$0.34(-0.44%)
At close: 4:00 PM EST
$83.49
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous CloseN/A
Volume53.78K
Average Volume (3M)1.04M
Market Cap
$3.95B
Enterprise Value$3.22B
Total Cash (Recent Filing)$296.43M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)24.4
Beta0.56
Next Earnings
Feb 10, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.27
Shares Outstanding46,809,673
10 Day Avg. Volume782,882
30 Day Avg. Volume1,041,280
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda8.60
Forecast
1Y Price Target
$83.13Price Target Upside-0.43% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)4.91
Revenue Forecast (FY)$1.32B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceShares rise 32% on Q2 beat, FY/26 guidance raised, bullish plasma outlook, and vascular closure stabilization.
Margin ExpansionHAE's gross margin was up 380 basis points year-over-year and its operating margin was up 250 basis points year-over-year.
Revenue GrowthPlasma sales excluding CSL grew approximately 19% in F2Q26.
Bears Say
Market Share LossThe company lost material market share in around 50 of its 500 key EP hospital accounts as competitors ramped efforts to either take back share or capture share utilizing very aggressive pricing.
Organic Growth DeclineHAE's organic growth slowed to a 1.8% decline in F2Q26 from 0.5% growth in F1Q26.
Top-Line DeclineThe likely top-line decline is primarily due to the winddown of the CSL relationship in U.S. plasma and the recent divestiture activity in the company’s blood center business.
Haemonetics News
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $3.95B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Feb 10, 2026 which is in 58 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Nov 06, 2025. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.16.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Overvalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.25.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 46,809,673 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.27 in its last earnings report, beating expectations of $1.11. Following the earnings report the stock price went up 32.315%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.13 (-0.43% Downside)
$83.13 (-0.43% Downside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 512.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $98.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.44%
12-Months-Change
Fundamentals
Return on Equity
19.47%
Trailing 12-Months
Asset Growth
-3.29%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation (HAE) is a global healthcare company focused on providing innovative solutions for blood and plasma management. The company primarily operates in the healthcare sector, delivering a range of products and services that enhance the safety, efficiency, and effectiveness of blood collection, processing, and transfusion. Haemonetics' core offerings include blood collection and processing systems, software solutions for blood management, and products related to the donation and transfusion of blood and blood components.
HAE Company Deck
HAE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in organic revenue, adjusted EPS, and gross margin expansion. Plasma and Blood Management Technologies showed robust performance, reinforcing strong cash generation and increased free cash flow guidance. However, overall revenue showed a decline due to portfolio transitions, and Interventional Technologies faced challenges. Despite these lowlights, the call maintained a positive outlook on future growth and profitability.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$83.13
▼(-0.43% Downside)
Technical Analysis
Ownership Overview
1.38% Insiders
42.54% Mutual Funds
25.80% Other Institutional Investors
4.45% Public Companies and
Individual Investors